Milic Jovana, Menozzi Valentina, Schepis Filippo, Malagoli Andrea, Besutti Giulia, Franconi Iacopo, Raimondi Alessandro, Carli Federica, Mussini Cristina, Sebastiani Giada, Guaraldi Giovanni
Modena HIV Metabolic Clinic.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia.
AIDS. 2020 Nov 1;34(13):1915-1921. doi: 10.1097/QAD.0000000000002650.
The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH).
This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018-2019.
Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP ≥248 dB/m), while significant liver fibrosis or cirrhosis (stage ≥F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates.
We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4 cell count 700 cells/μl, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6-15], vitamin D insufficiency (OR = 1.94, 1.2-3.2), obesity (OR = 8.1, 4.4-14.6), diabetes (OR = 3.2, 1.9-5.6), metabolic syndrome (OR = 2.41, 1.47-3.95) and osteoporosis (OR = 0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3-3.5), fibrosis (OR = 2, 1-3.7), NAFLD with fibrosis (OR = 9.2, 5.2-16.8), diabetes (OR = 1.7, 1-2.7) and multimorbidity (OR = 2.5, 1.5-4).
Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH.
本研究旨在调查肝脂肪变性和显著纤维化单独及联合存在(非酒精性脂肪性肝病伴纤维化)对作为评估HIV感染者(PLWH)生物学年龄指标的衰弱的影响。
这是一项对2018 - 2019年在摩德纳HIV代谢诊所就诊的连续患者进行的横断面研究。
排除有危险酒精摄入量和合并病毒型肝炎感染的患者。通过受控衰减参数(CAP)诊断肝脂肪变性,通过肝脏硬度测量(LSM)诊断肝纤维化。非酒精性脂肪性肝病定义为存在肝脂肪变性(CAP≥248 dB/m),而显著肝纤维化或肝硬化(F2期及以上)定义为LSM至少7.1 kPa。使用36项衰弱指数评估衰弱情况。采用逻辑回归,以脂肪变性和纤维化为协变量,探索衰弱的预测因素。
我们分析了707例PLWH(平均年龄53.5岁,76.2%为男性,CD4细胞计数中位数为700个/μl,98.7%的患者HIV RNA检测不到)。伴有纤维化的非酒精性脂肪性肝病占10.2%;分别有18.9%和3.9%的患者被分类为衰弱和极度衰弱。单因素分析表明,神经认知障碍[比值比(OR)=5.1,1.6 - 15]、维生素D不足(OR = 1.94,1.2 - 3.2)、肥胖(OR = 8.1,4.4 - 14.6)、糖尿病(OR = 3.2,1.9 - 5.6)、代谢综合征(OR = 2.41,1.47 - 3.95)和骨质疏松症(OR = 0.37,0.16 - 0.76)与伴有纤维化的非酒精性脂肪性肝病显著相关。衰弱指数的预测因素包括脂肪变性(OR = 2.1,1.3 - 3.5)、纤维化(OR = 2,1 - 3.7)、伴有纤维化的非酒精性脂肪性肝病(OR = 9.2,5.2 - 16.8)、糖尿病(OR = 1.7,1 - 2.7)和多种疾病并存(OR = 2.5,1.5 - 4)。
肝脂肪变性和伴有纤维化的非酒精性脂肪性肝病与衰弱相关。在预测衰弱方面,伴有纤维化的非酒精性脂肪性肝病超过了多种疾病并存的影响,这表明前者可作为PLWH代谢年龄的一个指标。